The enteric signaling network sends signals throughout the body. Kintai is focused on leveraging this interconnectivity to fight disease and restore health of patients. 


Kintai has invented a new class of precision-based therapeutics for multiple disease types.

The company’s initial pipeline includes an array of programs across autoimmune, metabolic, neurologic and cancer indications, including initiatives in ulcerative colitis, chronic kidney disease, NASH, metabolic syndrome and multiple sclerosis to name a few.

The company’s leadership is experienced in applying cutting-edge experimental medicine approaches to expedite development and increase probability of technical success. We are designing clinical trials to produce early proof of mechanism data by utilizing pharmacokinetic data and biomarkers of disease to determine whether we are impacting the desired pathways, and to capture the patient experience in the best way possible.

Ulcerative Colitis


Metabolic Syndrome


Progressive MS


Chronic Kidney Disease


Rare Disease


Gastroenterology 2


Cancer 1


Cancer 2


Cancer 3


Neurology 2


Infectious Disease


Lead Product Candidates

Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory bowel disease that results in the inflammation of the colon, leading to mucosal ulceration. Oral first-line treatments leave the majority of patients with persistent disease activity. There is a significant unmet need for oral treatments with improved benefit:risk for patients before they need biologic treatment. Kintai’s investigational PEM therapies, inspired by natural products and specific metabolites, aim to synergistically reduce inflammation in the lower gut and improve gut barrier function. Preclinical in vitro and in vivo models have consistently demonstrated that our compound has improved efficacy over standard of care. Based on these data, we are advancing quickly into the clinic.

Metabolic Syndrome and Obesity

Obesity increases a person’s risk of significant health problems, such as heart disease, stroke and diabetes. One third of the world population is overweight or obese. Kintai’s investigational PEM™ therapies leverage the ability of specific metabolites to reduce body weight, improve glucose tolerance, decrease inflammation and inhibit lipolysis. In preclinical models of obesity, treatment with our compounds resulted in a marked reduction in body weight and an improvement in lipid profile.

Chronic Kidney Disease

Chronic kidney disease is characterized by lasting damage to the kidneys that results in gradual loss of kidney function. Metabolites produced by gut bacteria, which are increased in case of renal impairment, have been shown to contribute to the progression of the disease, independent of the specific etiology. PEM™ compounds that inhibit metabolite production in the gut may break the vicious cycle, and improve renal outcome as well as decrease the mortality risk.